Effect of Peroxisome Proliferator-Activated Receptor Agonists on Serum Inflammatory Markers in Diabetic Rats

Document Type : Original Article(s)

Authors

1 Associate Professor, Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant professor, Department of Physiology, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran

3 Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Inflammation had a key role in several pathological conditions including atherosclerosis. Previous studies indicated that the proxisome proliferator-activated receptors (PPAR) are involved in numerous physiological and pathological conditions. The aim of this study was to investigate the effect of PPAR agonists including PPARα (fenofibrate), PPARβ/δ (GW0742), PPARγ (rosiglitazone) and pan PPAR (bezafibrate) administration on serum high-sensitive C-reactive protein (hsCRP) and interleukine-6 (IL-6) in male diabetic rats.Methods: The male Wistar rats were received streptozotocin for induction of type I diabetes. Then, they were randomly divided into five groups: diabetic, diabetic + fenofibrate (100 mg/kg/day; gavage), diabetic + GW0742 (1 mg/kg/day, subcutaneous), diabetic + rosiglitazone (8 mg/kg/day; gavage) and diabetic + bezafibrate (400mg/kg/day; gavage). After 21 days, the serum levels of hsCRP and IL-6 were measured using the enzyme-linked immunosorbent assay (ELISA) kits.Findings: Administration of different PPAR agonists did not alter serum hsCRP and IL-6 concentrations in diabetic animals.Conclusion: It seems that changes of serum inflammatory markers are not responsible for effects of PPARs agonist in atherosclerosis process and other mechanisms should be studied.

Keywords

References

  1. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32(9): 2045-51.
  2. Bisoendial RJ, Boekholdt SM, Vergeer M, Stroes ES, Kastelein JJ. C-reactive protein is a mediator of cardiovascular disease. Eur Heart J 2010; 31(17): 2087-91.
  3. Pradhan AD, Ridker PM. Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J 2002; 23(11): 831-4.
  4. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347(6294): 645-50.
  5. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000; 405(6785): 421-4.
  6. Touyz RM, Schiffrin EL. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vascul Pharmacol 2006; 45(1): 19-28.
  7. Jones AB. Peroxisome proliferator-activated receptor (PPAR) modulators: diabetes and beyond. Med Res Rev 2001; 21(6): 540-52.
  8. Bishop-Bailey D. Peroxisome proliferator-activated receptor beta/delta goes vascular. Circ Res 2008; 102(2): 146-7.
  9. Wang N. PPAR-delta in Vascular Pathophysiology. PPAR Res 2008; 2008: 164163.
  10. Zandbergen F, Plutzky J. PPARalpha in atherosclerosis and inflammation. Biochim Biophys Acta 2007; 1771(8): 972-82.
  11. Thieringer R, Fenyk-Melody JE, Le Grand CB, Shelton BA, Detmers PA, Somers EP, et al. Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo. J Immunol 2000; 164(2): 1046-54.
  12. Hill MR, Clarke S, Rodgers K, Thornhill B, Peters JM, Gonzalez FJ, et al. Effect of peroxisome proliferator-activated receptor alpha activators on tumor necrosis factor expression in mice during endotoxemia. Infect Immun 1999; 67(7): 3488-93.
  13. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001; 169(3): 453-9.
  14. Katayama A, Yamamoto Y, Tanaka K, Matsubara K, Sugitani M, Fujihara S, et al. Fenofibrate enhances neovascularization in a murine ischemic hindlimb model. J Cardiovasc Pharmacol 2009; 54(5): 399-404.
  15. Wagner N, Jehl-Pietri C, Lopez P, Murdaca J, Giordano C, Schwartz C, et al. Peroxisome proliferator-activated receptor beta stimulation induces rapid cardiac growth and angiogenesis via direct activation of calcineurin. Cardiovasc Res 2009; 83(1): 61-71.
  16. Wang CH, Ciliberti N, Li SH, Szmitko PE, Weisel RD, Fedak PW, et al. Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy. Circulation 2004; 109(11): 1392-400.
  17. Moraes LA, Piqueras L, Bishop-Bailey D. Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther 2006; 110(3): 371-85.
  18. Genovese S, De BG, Nicolucci A, Mannucci E, Evangelista V, Totani L, et al. Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes. Adv Ther 2013; 30(2): 190-202.
  19. Youssef J, Badr M. Role of peroxisome proliferator-activated receptors in inflammation control. J Biomed Biotechnol 2004; 2004(3): 156-66.
  20. Vijay SK, Mishra M, Kumar H, Tripathi K. Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes. Acta Diabetol 2009; 46(1): 27-33.
  21. Libby P, Plutzky J. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. Am J Cardiol 2007; 99(4A): 27B-40B.
Journal of Isfahan Medical School
Volume 32, Issue 277 - Serial Number 277
January and February 2014
Pages 256-261

Files

History

  • Receive Date: 22 September 2013
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics